Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fluorouracil + Hydroxyurea + Pamiparib + Tislelizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 14||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Hydroxyurea||Droxia||Carbamohydroxamic Acid|Hydroxycarbamide||Droxia (hydroxyurea) inhibits ribonucleoside diphosphate reductase, resulting in cell cycle arrest (NCI Drug Dictionary).|
|Pamiparib||BGB-290|BGB290||PARP Inhibitor (Pan) 26||Pamiparib (BGB-290) inhibits PARP1 and PARP2, potentially resulting in increased sensitivity to DNA damaging agents (AACR; 2015. Abstract nr 1651, PMID: 32652442).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 95||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05526924||Phase I||Fluorouracil + Hydroxyurea + Pamiparib + Tislelizumab||Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer||Not yet recruiting||USA||0|